Literature DB >> 26077380

FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK.

E McCloskey1, J A Kanis, H Johansson, N Harvey, A Odén, A Cooper, C Cooper, R M Francis, D M Reid, D Marsh, P Selby, F Thompson, S Hewitt, J Compston.   

Abstract

UNLABELLED: Under current guidelines, based on prior fracture probability thresholds, inequalities in access to therapy arise especially at older ages (≥70 years) depending on the presence or absence of a prior fracture. An alternative threshold (a fixed threshold from the age of 70 years) reduces this disparity, increases treatment access and decreases the need for bone densitometry.
INTRODUCTION: Several international guidelines set age-specific intervention thresholds at the 10-year probability of fracture equivalent to a woman of average BMI with a prior fracture. At older ages (≥70 years), women with prior fracture selected for treatment are at lower average absolute risk than those selected for treatment in the absence of prior fracture, prompting consideration of alternative thresholds in this age group.
METHODS: Using a simulated population of 50,633 women aged 50-90 years in the UK, with a distribution of risk factors similar to that in the European FRAX derivation cohorts and a UK-matched age distribution, the current NOGG intervention and assessment thresholds were compared to one where the thresholds remained constant from 70 years upwards.
RESULTS: Under current thresholds, 45.1% of women aged ≥70 years would be eligible for therapy, comprising 37.5% with prior fracture, 2.2% with high risk but no prior fracture and 5.4% selected for treatment after bone mineral density (BMD) measurement. Mean hip fracture probability was 11.3, 23.3 and 17.6%, respectively, in these groups. Under the alternative thresholds, the overall proportion of women treated increased from 45.1 to 52.9%, with 8.4% at high risk but no prior fracture and 7.0% selected for treatment after BMD measurement. In the latter group, the mean probability of hip fracture was identical to that observed in women with prior fracture (11.3%). The alternative threshold also reduced the need for BMD measurement, particularly at older ages (>80 years).
CONCLUSIONS: The alternative thresholds equilibrate fracture risk, particularly hip fracture risk, in those with or without prior fracture selected for treatment and reduce BMD usage at older ages.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077380     DOI: 10.1007/s00198-015-3176-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 2.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

3.  A comparison of case-finding strategies in the UK for the management of hip fractures.

Authors:  H Johansson; J A Kanis; A Oden; J Compston; E McCloskey
Journal:  Osteoporos Int       Date:  2012-01-11       Impact factor: 4.507

4.  Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.

Authors:  O Bruyère; M Fossi; B Zegels; L Leonori; M Hiligsmann; A Neuprez; J-Y Reginster
Journal:  Rheumatol Int       Date:  2012-07-28       Impact factor: 2.631

5.  The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study.

Authors:  Sansin Tuzun; Nurten Eskiyurt; Ulku Akarirmak; Merih Saridogan; Helena Johansson; Eugene McCloskey; John A Kanis
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617

6.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 7.  [Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis].

Authors:  Hiroshi Hagino
Journal:  Clin Calcium       Date:  2014-01

8.  The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.

Authors:  B Dawson-Hughes; A C Looker; A N A Tosteson; H Johansson; J A Kanis; L J Melton
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

9.  Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Authors:  J Compston; A Cooper; C Cooper; R Francis; J A Kanis; D Marsh; E V McCloskey; D M Reid; P Selby; M Wilkins
Journal:  Maturitas       Date:  2009-01-08       Impact factor: 4.342

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

View more
  16 in total

1.  Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464).

Authors:  N C Harvey; E McCloskey; J A Kanis; J Compston; C Cooper
Journal:  Osteoporos Int       Date:  2018-06-08       Impact factor: 4.507

2.  Underestimated fracture risk in postmenopausal women-application of the hybrid intervention threshold.

Authors:  Y Wang; S Yu; C Hsu; C Tsai; T Cheng
Journal:  Osteoporos Int       Date:  2019-11-06       Impact factor: 4.507

3.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

Review 4.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

5.  The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.

Authors:  M Chakhtoura; W D Leslie; M McClung; A M Cheung; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2016-09-20       Impact factor: 4.507

6.  Novel algorithm generating strategy to identify high fracture risk population using a hybrid intervention threshold.

Authors:  Chung-Yuan Hsu; Chih-Hsing Wu; Shan-Fu Yu; Yu-Jih Su; Wen-Chan Chiu; Ying-Chou Chen; Han-Ming Lai; Jia-Feng Chen; Chi-Hua Ko; Jung-Fu Chen; Tien-Tsai Cheng
Journal:  J Bone Miner Metab       Date:  2019-10-03       Impact factor: 2.626

7.  Is drug-induced bone loss acceptable in premenopausal women? A practical fracture risk modeling exercise.

Authors:  N Binkley; R Besuyen; T Fuerst; L Skillern; D Hans
Journal:  Osteoporos Int       Date:  2017-10-10       Impact factor: 4.507

8.  FRAX-based osteoporosis treatment guidelines for resource-poor settings in India.

Authors:  Lakshmi Nagendra; Nisha Bhavani; V Usha Menon; Praveen V Pavithran; Arun S Menon; Nithya Abraham; Vasantha Nair; Harish Kumar
Journal:  Arch Osteoporos       Date:  2021-04-14       Impact factor: 2.617

9.  Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Authors:  M Chandran; P J Mitchell; T Amphansap; S K Bhadada; M Chadha; D-C Chan; Y-S Chung; P Ebeling; N Gilchrist; A Habib Khan; P Halbout; F L Hew; H-P T Lan; T C Lau; J K Lee; S Lekamwasam; G Lyubomirsky; L B Mercado-Asis; A Mithal; T V Nguyen; D Pandey; I R Reid; A Suzuki; T T Chit; K L Tiu; T Valleenukul; C K Yung; Y L Zhao
Journal:  Osteoporos Int       Date:  2021-01-27       Impact factor: 4.507

10.  Long-Term Treatment of Postmenopausal Osteoporosis.

Authors:  Jacques P Brown
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.